ArticleMaterials (Basel, Switzerland)2022
Laboratory Experiments on the In Situ Upgrading of Heavy Crude Oil Using Catalytic Aquathermolysis by Acidic Ionic Liquid.
Article in Materials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 19 citations in OpenAlex.
- In Situ Heavy Crude Oil Upgrading via Catalytic Aquathermolysis with a Nickel-Based Catalyst Deposited Over a Rock Matrix.ACS omega · 2026Article
- In-situ upgrading of Egyptian heavy crude oil using matrix polymer carboxyl methyl cellulose/silicate graphene oxide nanocomposites.Scientific reports · 2024Article
- Experimental and computational studies of novel cyclic ammonium based ionic liquids as corrosion inhibitors for carbon steel in acid medium.Scientific reports · 2024Article
- Dicationic ionic liquids (DILs) as rapid esterification catalyst of butyric fatty acid.Scientific reports · 2023Article
- Investigation the effect of different ionic liquids based-aryl imidazole on the onset precipitation of asphaltene.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Heavy and extra heavy oil exploitation has attracted attention in the last few years because of the decline in the production of conventional crude oil. The high viscosity of heavy crude oil is the main challenge that obstructs its extraction. Consequently, catalytic aquathermolysis may be an effective solution to upgrade heavy crude oil to decrease its viscosity in reservoir conditions. In this regard, a series of acidic ionic liquids, 1-butyl-1H-imidazol-3-ium 4-dodecylbenzenesulfonate (IL-4), 1-decyl-1H-imidazol-3-ium 4-dodecylbenzenesulfonate (IL-10), and 1-hexadecyl-1H-imidazol-3-ium 4-dodecylbenzenesulfonate (IL-16), were utilized in the aquathermolysis of heavy crude oil. Of each IL, 0.09 wt % reduced the viscosity of the crude oil by 89%, 93.7%, and 94.3%, respectively, after the addition of 30% water at 175 °C. ILs with alkyl chains equal to 10 carbon atoms or more displayed greater activity in viscosity reduction than that of ILs with alkyl chains lower than 10 carbon atoms. The molecular weight and asphaltene content of the crude oil were decreased after catalytic aquathermolysis. The compositional analysis of the crude oil before and after catalytic aquathermolysis showed that the molar percentage of lighter molecules from tridecanes to isosanes was increased by 26-45%, while heavier molecules such as heptatriacontanes, octatriacontanes, nonatriacontanes, and tetracontanes disappeared. The rheological behavior of the crude oil before and after the catalytic aquathermolytic process was studied, and the viscosity of the crude oil sample was reduced strongly from 678, 29.7, and 23.4 cp to 71.8, 16.9, and 2.7 cp at 25, 50, and 75 °C, respectively. The used ILs upgraded the heavy crude oil at a relatively low temperature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.